Stay updated with breaking news from Reproductive Scientist Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Strong antibody response to mRNA vaccines declined over an eight-month follow-up period; lower initial response to single-shot Ad26 vaccine remained
Newswise — Boston – Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age women. Increases in preterm birth and still birth have also been observed in pregnancies complicated by the viral infection. The Centers for Disease Control and Prevention (CDC) recommended that people who are pregnant may choose to be vaccinated at their own discretion with their healthcare provider. However, pregnant and lactating women were not included in Phase 3 vaccine efficacy trials; thus, data...
This figure presents serum binding and functional antibody responses following COVID-19 vaccination and SARS-CoV-2 infection among women 45 years or younger. A and B, Each panel compares vaccine antibody responses at 2 through 8 weeks after the second dose to nonpregnant and pregnant women who were unvaccinated and infected. Thirteen women (7 nonpregnant, 4 pregnant, and 2 lactating) who had baseline samples collected within 7 days of their first vaccine dose were selected based on the earliest sample availability and were analyzed as a negative assay control. C, D, and E, Systems serology wa...
E-Mail Boston - Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age women. Increases in preterm birth and still birth have also been observed in pregnancies complicated by the viral infection. The Centers for Disease Control and Prevention (CDC) recommended that people who are pregnant may choose to be vaccinated at their own discretion with their healthcare provider. However, pregnant and lactating women were not included in Phase 3 vaccine efficacy trials; thus, data on va...
Amanda Kallen, MD Dr. Amanda N. Kallen is a Yale Medicine reproductive endocrinologist and an assistant professor of obstetrics and gynecology at the Yale School of Medicine, as well as a member of the Reproductive Scientist Development Program (RSDP). She obtained her medical degree at the University of Connecticut and completed her residency in obstetrics and gynecology at Yale-New Haven Hospital, followed by a fellowship in reproductive endocrinology and infertility at the Yale School of Medicine. During her fellowship, she was accepted into the RSDP scholar program, an NIH-funded physicia...